City Therapeutics, Inc. filed Amendment No. 1 to its Form S-1 registration statement with the SEC on October 9, 2026, seeking to raise proceeds from an initial public offering of 9,722,222 shares of common stock at an estimated price range of $17.00 to $19.00 per share.

Key Highlights

  • Shares offered: City Therapeutics is offering 9,722,222 shares of common stock in its initial public offering, according to the filing.
  • Price range: The estimated initial public offering price per share is between $17.00 and $19.00, as stated in the prospectus.
  • Overallotment option: The underwriters have been granted an option to purchase up to an additional 1,458,333 shares from the company at the IPO price, less underwriting discounts and commissions.
  • Proposed listing: The company has applied to list its common stock on the Nasdaq Global Market under the symbol "CTY," and the filing states that completion of the offering is contingent upon such listing.
  • Company classification: City Therapeutics has identified itself as a non-accelerated filer, a smaller reporting company, and an emerging growth company under U.S. federal securities laws.
  • Lead underwriters: Goldman Sachs and Co. LLC, Jefferies, Stifel, and Oppenheimer and Co. are listed as underwriters for the offering.

City Therapeutics Seeks Nasdaq Listing in Initial Public Offering

City Therapeutics, Inc., a Delaware-incorporated biopharmaceutical company headquartered at 399 Binney Street, Cambridge, MA 02142, filed Amendment No. 1 to its Form S-1 registration statement (Registration No. 333-299117) with the SEC on October 9, 2026. The filing covers a proposed initial public offering of 9,722,222 shares of common stock. According to the prospectus, prior to this offering, there has been no public market for the company's common stock.

The company disclosed that the estimated initial public offering price per share will be between $17.00 and $19.00. City Therapeutics has applied to list its shares on the Nasdaq Global Market under the ticker symbol "CTY," and the filing states that "the completion of this offering is contingent upon such listing." The underwriters have been granted an option to purchase up to an additional 1,458,333 shares at the IPO price, less underwriting discounts and commissions. Goldman Sachs and Co. LLC, Jefferies, Stifel, and Oppenheimer and Co. are named as underwriters. The filing notes that underwriting discounts, commissions, and related compensation are detailed in the "Underwriting" section of the prospectus.

City Therapeutics identified itself as an emerging growth company and a smaller reporting company under U.S. federal securities laws, and the filing indicates the company has elected to comply with certain reduced reporting requirements. Andrew Orth, M.B.A., is named as President and Chief Executive Officer. The company's primary SIC code is listed as 2834. The registration statement notes that the information in the preliminary prospectus is not complete and may be changed, and that securities may not be sold until the registration statement is effective. The filing also contains cautionary language noting that forward-looking statements are subject to risks and uncertainties described in the "Risk Factors" section beginning on page 14 of the prospectus.

What Was Disclosed

City Therapeutics filed an amended S-1 registration statement on October 9, 2026, disclosing a proposed IPO of 9,722,222 shares at an estimated $17.00 to $19.00 per share, an underwriter overallotment option for up to 1,458,333 additional shares, and a pending application to list on the Nasdaq Global Market under "CTY."